Researchers at NYU Langone Health discovered that blocking lipocalin 2 (LCN2), a protein produced by stressed cancer cells, enhances the effectiveness of immunotherapies in mice by enabling the immune system to better target tumor cells. This breakthrough could lead to new treatments for aggressive cancers resistant to current immunotherapy methods, offering hope for improved patient outcomes.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.



